Bifogade filer
Minutes from AGM Vistin Pharma ASA_23 may 2024
Kurs
+1,82%
Likviditet
0,01 MNOK
Kalender
| Tid* | ||
| 2024-11-06 | - | X-dag bonusutdelning VISTN 0.5 |
| 2024-11-06 | - | X-dag halvårsutdelning VISTN 0.5 |
| 2024-10-31 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-23 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-05 | - | X-dag bonusutdelning VISTN 0.5 |
| 2024-06-05 | - | X-dag halvårsutdelning VISTN 0.5 |
| 2024-05-23 | - | Årsstämma |
| 2024-04-24 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-16 | - | Bokslutskommuniké 2023 |
| 2024-01-23 | - | X-dag ordinarie utdelning VISTN 0.75 NOK |
| 2024-01-23 | - | X-dag bonusutdelning VISTN 0.75 |
| 2023-10-25 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-23 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-23 | - | X-dag ordinarie utdelning VISTN 0.00 NOK |
| 2023-05-22 | - | Årsstämma |
| 2023-04-27 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-17 | - | Bokslutskommuniké 2022 |
| 2022-10-26 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-19 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-24 | - | X-dag ordinarie utdelning VISTN 0.00 NOK |
| 2022-05-19 | - | Årsstämma |
| 2022-04-27 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-10-28 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-21 | - | X-dag ordinarie utdelning VISTN 0.50 NOK |
| 2021-05-21 | - | X-dag bonusutdelning VISTN 0.5 |
| 2021-05-20 | - | Årsstämma |
| 2021-04-23 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-19 | - | Bokslutskommuniké 2020 |
| 2020-10-30 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-28 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-24 | - | Extra Bolagsstämma 2020 |
| 2020-05-20 | - | X-dag ordinarie utdelning VISTN 1.00 NOK |
| 2020-05-19 | - | Årsstämma |
| 2020-04-23 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-10-25 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-29 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | - | X-dag ordinarie utdelning VISTN 0.00 NOK |
| 2019-05-22 | - | Årsstämma |
| 2019-04-25 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-19 | - | Bokslutskommuniké 2018 |
| 2018-10-25 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-30 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-25 | - | X-dag ordinarie utdelning VISTN 1.00 NOK |
| 2018-05-08 | - | Årsstämma |
| 2018-04-26 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-27 | - | Bokslutskommuniké 2017 |
| 2017-11-03 | - | X-dag bonusutdelning VISTN 7 |
| 2017-11-02 | - | Extra Bolagsstämma 2017 |
| 2017-10-27 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-31 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-26 | - | X-dag ordinarie utdelning VISTN 1.00 NOK |
| 2017-05-24 | - | Årsstämma |
| 2017-04-26 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-28 | - | Bokslutskommuniké 2016 |
| 2016-10-31 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-30 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-25 | - | X-dag ordinarie utdelning VISTN 0.60 NOK |
| 2016-05-24 | - | Årsstämma |
| 2016-04-28 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-23 | - | Bokslutskommuniké 2015 |
| 2015-10-29 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-26 | - | Kvartalsrapport 2015-Q2 |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Oslo, Norway, 23 May 2024
Vistin Pharma ASA (OSE: VISTN), please find attached the minutes from the annual general meeting held today, on the 23 May 2024. All matters were resolved as proposed in the call for the annual general meeting, including the proposal to distribute a dividend of total NOK 1 per share, to be paid partly in June (NOK 0.5) and November (NOK 0.5).
For the June dividend of NOK 0.5 per share, the shares will be traded excluding the right (ex-date) on the 5th of June, with payment date on or about 18 June 2024.
For the November dividend of NOK 0.5 per share, the shares will be traded excluding the right (ex-date) on the 6th of November, with payment date on or about 19 November 2024 .
For further information, please contact:
Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.